Why carry out this study?

Efficacy and safety of insulin glargine 300 U/mL (Gla-300) has been demonstrated in randomised clinical trials and real-world studies conducted in the USA and Western Europe.

ATOS study evaluated the use of Gla-300 in real-world populations across Asia, the Middle East, North Africa, Latin America and Eastern Europe.

What was learned from the study?

Initiation of Gla-300 in insulin-naïve participants with type 2 diabetes after failure of oral anti-hyperglycaemic drugs, showed an improvement in glycaemic control with an adequate safety profile.

On the basis of the current study results, in a real-world clinical setting, Gla-300 can be a treatment choice for people with type 2 diabetes who are insufficiently controlled with oral anti-hyperglycaemic drugs across the five regions of the world with diverse clinical profiles and treatment practices.